GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Rhea-AI Summary

GenMark Diagnostics (NASDAQ: GNMK) has announced it will release its fourth quarter and full year earnings results on February 25, 2021, after market close. A conference call to discuss the financial performance will be held at 4:30 p.m. ET, which will also be available via webcast. GenMark specializes in multiplex molecular diagnostic solutions aimed at enhancing patient care and reducing healthcare costs, utilizing its proprietary eSensor® technology across a range of infectious disease tests.

Positive

• Scheduled earnings release may indicate confidence in financial performance.
• Company's focus on multiplex molecular diagnostics positions it well in a growing market.

Negative

• None.

CARLSBAD, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Thursday, February 25, 2021. Management will hold a conference call to review the company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast.

The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 6957136 approximately five minutes prior to the start time.

ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.

Investor Relations Contact
Leigh Salvo
(415) 937-5404
ir@genmarkdx.com

FAQ

When will GenMark Diagnostics release its fourth quarter earnings results?

GenMark Diagnostics will release its fourth quarter earnings results on February 25, 2021, after market close.

What is the time for GenMark's earnings conference call?

The earnings conference call for GenMark Diagnostics is scheduled for 4:30 p.m. ET on February 25, 2021.

How can I access the GenMark Diagnostics conference call?

The conference call can be accessed by dialing (877) 312-5847 for US/Canada or (253) 237-1154 for international callers, using conference ID 6957136.

What technologies does GenMark Diagnostics utilize in its products?

GenMark Diagnostics utilizes its proprietary eSensor® detection technology in its eSensor XT-8® and ePlex® systems for molecular diagnostics.